<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961478</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC2015-06</org_study_id>
    <nct_id>NCT02961478</nct_id>
  </id_info>
  <brief_title>Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure</brief_title>
  <acronym>IOXSOR</acronym>
  <official_title>Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IOXSOR study's purpose to determine the frequency of non resolutive renal failure (estimated
      by the clearance of iohexol) at end of stay in ICU patients who have had acute renal failure
      episode.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of patients with a clearance of iohexol &lt; 60 ml/min/1m273 at the end of ICU hospitalisation.</measure>
    <time_frame>24 hours</time_frame>
    <description>Iohexol clearance pharmacokinetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between non resolutive renal at the end of ICU (iohexol clearance &lt; 60 ml/min/1m273) and creatinine clearance &lt; 60 ml/min/1m273 at 6 month after ICU. discharge</measure>
    <time_frame>Six month after ICU discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of risk factors associated with non resolutive among : Age Previous renal function Comorbidities Severity parameters of renal aggression Acute severity of parameters during the ICU hospitalisation</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between serum creatinine derived measurements of Glomerular Filtratio Rate and iohexol clearance.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acute Renal Failure</condition>
  <arm_group>
    <arm_group_label>Iohexol plasmatic clearance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IOHEXOL</intervention_name>
    <description>Estimate iohexol clearance at the end of stay in intensive care for patients who had an episode of acute renal failure.</description>
    <arm_group_label>Iohexol plasmatic clearance</arm_group_label>
    <other_name>Omnipaque ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICU stay &gt; 7 days

          -  Having presented during the stay renal failure stage 2 or 3 Kidney Disease Improving
             Global Outcomes (KDIGO)

          -  Steady improvement of renal function before the ICU discharge :

               -  Creatinine before ICU discharge &lt;110 µmol / L for women, &lt;130 µmol / L for men

               -  No recourse to extra renal purification

               -  Change in creatinine levels (ΔCréatinine) less than 20% over two measures spaced
                  24 hours within 48 hours preceding the discharge

          -  Expected discharge ICU within 48 hours :

               -  Glasgow score &gt; 13

               -  Lack of mechanical ventilation except home Noninvasive Mechanical Ventilation
                  (NiMV)

               -  Lack of use of catecholamine

               -  No contra-indication for discharge according to physician in charge of the
                  patient

          -  Informed consent signed by the patient, where not possible by the person of trust or
             the family if present. Written consent by the patient will be obtained as soon as
             deemed possible.

        Exclusion Criteria:

          -  Iohexol administration within 48 hours preceding the potential inclusion (imaging
             examination with X-ray contrast medium injection)

          -  Iohexol administration planned within 24 hours after potential inclusion in the study

          -  Known medical history of immediate allergic or delayed skin allergic reaction to
             injection of iodinated contrast material or any serious doubt on this medical history

          -  Patient receiving from extra renal purification during ICU discharge

          -  Chronic renal disease known (creatinine&gt; 110 µmol / L for women,&gt; 130 µmol / L for
             men) or creatinine clearance estimated less than 60 mL / min

          -  Pregnancy or breastfeeding women

          -  Patient under guardianship or safeguard justice known at the time of inclusion

          -  Patient limitation care

          -  Person not affiliated or not the beneficiary of a social security scheme
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François BELONCLE, CCU-AH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François BELONCLE, CCU-AH</last_name>
    <phone>0241353845</phone>
    <email>Francois.Beloncle@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolas LEROLLE, MD PhD</last_name>
    <phone>0241353845</phone>
    <email>NiLerolle@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François BELONCLE, CCU-AH</last_name>
      <phone>0241353845</phone>
      <email>Francois.Beloncle@chu-angers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nicolas LEROLLE, MD PhD</last_name>
      <phone>0241353845</phone>
      <email>NiLerolle@chu-angers.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital center</name>
      <address>
        <city>Chartres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre CONIA, MD</last_name>
      <phone>02 37 30 30 30</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrice TIROT, MD</last_name>
      <phone>02 43 43 24 58</phone>
      <email>ptirot@ch-lemans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René Robert, MD PhD</last_name>
      <phone>05 49 44 43 67</phone>
      <email>rene.robert@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan EHRMANN, MD PhD</last_name>
      <phone>02 47 47 38 55</phone>
      <email>StephanEHRMANN@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte SALMON, MD</last_name>
      <phone>02 47 47 37 18</phone>
      <email>charlotte.salmon.gandonniere@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

